Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUVIEW(R) Digital Cytology Microscope - Transforming Veterinary Imaging
Zomedica (OTCQB:ZOMDF) announces its upcoming Fourth Friday at Four webinar on September 26, 2025 at 4:00 PM ET, featuring their TRUVIEW digital cytology microscope. The webinar will showcase how TRUVIEW is revolutionizing veterinary diagnostics by enabling the creation of automated laboratory-quality blood films from fresh blood samples.
The TRUVIEW system addresses historical challenges in veterinary practices by eliminating technical barriers to blood film preparation, allowing clinics to return to gold-standard protocols. The technology uniquely enables blood film analysis before cell bloat occurs from EDTA preservatives, marking a significant advancement in point-of-care diagnostics.
Zomedica (OTCQB:ZOMDF) annuncia il prossimo webinar Fourth Friday at Four, in programma per 26 settembre 2025 alle 16:00 ET, in cui si presenterà il microscopio diagnostico digitale TRUVIEW. L'evento mostrerà come TRUVIEW stia rivoluzionando la diagnostica veterinaria, permettendo la creazione automatica di campioni di sangue di qualità da laboratorio partendo da campioni di sangue freschi.
Il sistema TRUVIEW affronta le sfide storiche nelle pratiche veterinarie eliminando le barriere tecniche nella preparazione dei film di sangue, consentendo alle cliniche di tornare alle protocolli gold standard. La tecnologia permette analisi dei film di sangue prima che si verifichi il rigonfiamento cellulare dovuto ai conservanti EDTA, segnando un significativo avanzamento nella diagnostica sul campo.
Zomedica (OTCQB:ZOMDF) anuncia su próximo seminario web Fourth Friday at Four, que se llevará a cabo el 26 de septiembre de 2025 a las 4:00 PM ET, y contará con el microscopio digital de citología TRUVIEW. El webinar mostrará cómo TRUVIEW está revolucionando el diagnóstico veterinario al permitir la creación automática de láminas sanguíneas de calidad de laboratorio a partir de muestras de sangre frescas.
El sistema TRUVIEW aborda los desafíos históricos en las clínicas veterinarias al eliminar las barreras técnicas para la preparación de láminas de sangre, permitiendo que las clínicas vuelvan a seguir protocolos de oro. La tecnología facilita el análisis de láminas sanguíneas antes de que ocurra la hinchazón de células debido a los conservantes EDTA, marcando un avance significativo en el diagnóstico en el punto de atención.
Zomedica (OTCQB:ZOMDF)는 2025년 9월 26일 오후 4:00(Eastern Time)에 열리는 Fourth Friday at Four 웨비나를 발표하며, TRUVIEW 디지털 세포학 현미경를 선보입니다. 이 웨비나는 TRUVIEW가 신선한 혈액 샘플로부터 자동화된 실험실 품질의 혈액 도말을 가능하게 함으로써 수의학 진단에 혁신을 가져오는 모습을 보여줄 것입니다.
TRUVIEW 시스템은 혈액 도말 준비의 기술적 장벽을 제거해 수의 진료소가 금표준 프로토콜로 돌아갈 수 있도록 하며, EDTA 보존제로 인한 세포 팽창이 일어나기 전에 혈액 도말 분석을 가능하게 하는 기술적 차별점을 통해 현장 진단의 중요한 발전을 이루고 있습니다.
Zomedica (OTCQB:ZOMDF) annonce son prochain webinaire Fourth Friday at Four, le 26 septembre 2025 à 16h00 ET, mettant en avant le microscope digital de Cytologie TRUVIEW. Le webinaire mettra en lumière comment TRUVIEW révolutionne le diagnostic vétérinaire en permettant la création automatique de lames sanguines de qualité laboratoire à partir d’échantillons de sang frais.
Le système TRUVIEW répond aux défis historiques des pratiques vétérinaires en éliminant les barrières techniques à la préparation des lames sanguines, permettant ainsi aux cliniques de revenir à des protocoles de référence. La technologie permet l’analyse des lames sanguines avant que le gonflement des cellules dû aux conservateurs EDTA ne se produise, marquant une avancée significative dans le diagnostic au point de soins.
Zomedica (OTCQB:ZOMDF) kündigt das kommende Fourth Friday at Four-Webinar am 26. September 2025 um 16:00 Uhr ET an und präsentiert dabei das TRUVIEW Digitalkytologie-Mikroskop. Das Webinar veranschaulicht, wie TRUVIEW die veterinärmedizinische Diagnostik revolutioniert, indem automatische, laborqualitätsgerechte Blutfilme aus frischen Blutproben erstellt werden können.
Das TRUVIEW-System adressiert historische Herausforderungen in tierärztlichen Praxen, indem es technische Barrieren bei der Vorbereitung von Blutfilmen beseitigt und Kliniken die Rückkehr zu Goldstandard-Protokollen ermöglicht. Die Technologie ermöglicht eine Blutfilm-Analyse, bevor Zellaufschwemmung durch EDTA-Konservierung eintritt, und markiert einen wesentlichen Fortschritt in der Point-of-Care-Diagnostik.
Zomedica (OTCQB:ZOMDF) تعلن عن الندوة القادمة Fourth Friday at Four يوم 26 سبتمبر 2025 الساعة 4:00 مساءً بتوقيت الشرقية، مع عرض المجهر الرقمي للخلية TRUVIEW. ستعرض الندوة كيف يحدث TRUVIEW ثورة في تشخيص الحيوانات من خلال تمكين إنشاء شرائح دم عالية الجودة مخبريًا تلقائيًا من عينات الدم الطازجة.
يحل نظام TRUVIEW التحديات التاريخية في ممارسات الطب البيطري من خلال إزالة العوائق التقنية لإعداد شرائح الدم، مما يسمح للعيادات بالعودة إلى بروتوكولات المعيار الذهبي. التكنولوجيا تتيح تحليل شرائح الدم قبل حدوث تضخم الخلايا نتيجةً للمحافظ EDTA، وهو تقدم مهم في تشخيص نقطة الرعاية.
Zomedica (OTCQB:ZOMDF) 宣布将于2025年9月26日美国东部时间下午4:00举行第四个周五四点网络研讨会，届时将展示他们的TRUVIEW数字细胞学显微镜。该网络研讨会将展示TRUVIEW如何通过从新鲜血样中自动创建实验室级别的血涂片，革新兽医诊断。
TRUVIEW系统通过消除制备血涂片的技术障碍，解决了兽医实践中的历史性挑战，使诊所能够回归金标准协议。该技术独特之处在于在EDTA防腐剂导致细胞膨胀之前即可进行血涂片分析，标志着点前诊断的重大进步。
- None.
- None.
Cutting-Edge Digital Microscopy System Featured in Monthly Series Showcasing Innovation in Veterinary Care
ANN ARBOR, MI / ACCESS Newswire / September 12, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering advanced diagnostic and therapeutic solutions for companion and equine animals, is pleased to announce the next installment of its Fourth Friday at Four webinar series, scheduled for Friday, September 26 at 4:00 PM ET, featuring the TRUVIEW digital cytology microscope.
This month's feature will highlight how the TRUVIEW microscope is redefining digital cytology and hematology in veterinary practice by providing rapid, high-quality image capture and interpretation. For the first time in the industry, veterinarians now have the ability to create an automated laboratory-quality blood film on fresh blood-prior to the natural cell bloat caused by EDTA preservatives.
It is well known that best practices require blood films on all blood drawn from a patient. Historically, many clinics have moved away from this standard, not because the practice was incorrect, but due to the lack of technical skill or resources to reliably prepare high-quality slides at the point of care. With the TRUVIEW microscope, those barriers are eliminated, empowering clinicians to return to gold-standard protocols with speed, consistency, and confidence.
What to Expect:
Demonstration of the TRUVIEW microscope's digital imaging and blood film preparation capabilities
Insights into how rapid cytology is enhancing diagnostic confidence in clinics
Discussion of best practices for blood films and how the TRUVIEW microscope enables their adoption at the point of care
Case studies showcasing real-world improvements in patient outcomes
Interactive Q&A with Zomedica's leadership and imaging experts
"Zomedica's TRUVIEW microscope brings speed and precision to cytology, which is one of the most critical diagnostic tools veterinarians rely upon," said Bill Campbell, VP of Imaging at Zomedica. "The ability to prepare and analyze a true laboratory-quality blood film on fresh blood, right in the clinic, marks a fundamental shift in veterinary diagnostics."
"Our Fourth Friday series is all about shining a light on innovations that elevate the standard of care in veterinary medicine," said Larry Heaton, CEO of Zomedica. "The TRUVIEW microscope is a perfect example of how our diagnostics portfolio is designed to help veterinarians deliver better outcomes, improve efficiency, and enhance the overall practice experience."
Register for the Webinar
Don't miss your chance to connect with industry experts, get a firsthand look at groundbreaking veterinary technologies, and explore what's next in animal healthcare. Whether you're a veterinary professional, industry partner, investor, or simply passionate about helping our pets live healthier lives, this series is for you.
https://sholink.to/FourthFridayinSeptember
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
FAQ
When is Zomedica's (ZOMDF) next Fourth Friday at Four webinar and what will it feature?
What are the key benefits of Zomedica's TRUVIEW digital cytology microscope?
How does the TRUVIEW microscope improve veterinary practice workflow?
Who will be presenting at Zomedica's September 2025 Fourth Friday webinar?
